Supernus Pharmaceuticals, Inc.
DE ˙ DB ˙ US8684591089
37,80 € 0,00 (0,00%)
2026-06-04
AKTIENPREIS
SecurityDE:S49 / Supernus Pharmaceuticals, Inc.
InstitutionMillennium Management Llc
ManagerIsrael Englander
Latest Disclosed Ownership3,281,615 shares
Ownership 5.70%
Millennium Management Llc ownership in S49 / Supernus Pharmaceuticals, Inc.

2026-02-18 - Millennium Management Llc has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 3,281,615 shares of Supernus Pharmaceuticals, Inc. (DE:S49). This represents 5.7 percent ownership of the company. In their previous filing dated 2026-02-02 , Millennium Management Llc had reported owning 3,036,123 shares, indicating an increase of 8.09 percent.

Millennium Management Llc has a history of taking positions in derivatives of the underlying security (S49) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date
Effective
Date
Form Prev
Shares
Latest
Shares
ΔShares
(Percent)
Ownership
(Percent)
ΔOwnership
(Percent)
2026-02-18 2026-02-18 13G/A 3,036,123 3,281,615 8.09 5.70 7.55
2026-02-02 2026-02-02 13G 3,036,123 5.30

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

DE:S49 / Supernus Pharmaceuticals, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 3,315,973 675,907 25.60 171,403 30.63 0.0713
2026-02-17 2025-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 2,640,066 2,293,773 662.38 131,211 692.86 0.0552
2025-11-14 2025-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 346,293 333,220 2,548.92 16,549 3,916.75 0.0071
2025-08-14 2025-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 13,073 -130,283 -90.88 412 -91.22 0.0002
2025-05-15 2025-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 143,356 112,886 370.48 4,695 326.34 0.0025
2025-02-14 2024-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 30,470 -222,273 -87.94 1,102 -86.03 0.0005
2024-11-14 2024-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 252,743 91,411 56.66 7,881 82.62 0.0037
2024-08-14 2024-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 161,332 128,743 395.05 4,316 288.39 0.0020
2024-05-15 2024-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 32,589 -141,999 -81.33 1,112 -78.01 0.0005
2024-02-14 2023-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 174,588 96,383 123.24 5,053 134.32 0.0022
2023-11-14 2023-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 78,205 -55,270 -41.41 2,156 -46.26 0.0011
2023-08-14 2023-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 133,475 104,938 367.73 4,012 288.01 0.0020
2023-05-15 2023-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 28,537 -424,911 -93.71 1,034 -93.61 0.0006
2023-02-14 2022-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 453,448 453,448 16,174 0.0089
2022-11-14 2022-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 0 -244,223 -100.00 0 -100.00
2022-08-15 2022-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 244,223 244,223 7,063 0.0044
2022-05-16 2022-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 0 -91,662 -100.00 0 -100.00
2022-02-14 2021-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 91,662 -325,862 -78.05 2,673 -75.99 0.0014
2021-11-15 2021-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 417,524 312,679 298.23 11,135 244.95 0.0067
2021-08-16 2021-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 104,845 84,313 410.64 3,228 500.00 0.0020
2021-05-17 2021-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 20,532 11,673 131.76 538 141.26 0.0004
2021-02-16 2020-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 8,859 -1,930 -17.89 223 -0.89 0.0002
2020-11-16 2020-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 10,789 -19,406 -64.27 225 -68.62 0.0003
2020-08-14 2020-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 30,195 30,195 717 0.0010
2020-05-14 2020-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 0 -859,076 -100.00 0 -100.00
2020-02-14 2019-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 859,076 361,525 72.66 20,377 49.04 0.0255
2019-11-14 2019-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 497,551 167,378 50.69 13,672 25.14 0.0216
2019-08-15 2019-06-30 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 330,173 -129,135 -28.12 10,925 -32.12 0.0164
2019-08-14 2019-06-30 13F BEYOND MEAT COM 868459108 2,137 -457,171 343
2019-05-14 2019-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 459,308 179,305 64.04 16,094 73.02 0.0241
2019-02-15 2018-12-31 13F/A-1 SUPERNUS PHARMACEUTICALS COM 868459108 280,003 48,255 20.82 9,302 -20.28 0.0145
2019-02-14 2018-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 280,003 9,302
2018-11-14 2018-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 231,748 69,931 43.22 11,669 20.49 0.0143
2018-08-14 2018-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 161,817 -261,111 -61.74 9,685 -50.00 0.0126
2018-05-15 2018-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 422,928 -108,469 -20.41 19,370 -8.53 0.0258
2018-02-14 2017-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 531,397 -3,112 -0.58 21,176 -0.95 0.0292
2017-11-14 2017-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 534,509 525,974 6,162.55 21,380 5,709.78 0.0326
2017-08-14 2017-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 8,535 -564,403 -98.51 368 -97.95 0.0007
2017-05-15 2017-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 572,938 285,507 99.33 17,933 147.08 0.0329
2017-02-14 2016-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 287,431 -25,927 -8.27 7,258 -6.34 0.0152
2016-11-14 2016-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 313,358 -234,231 -42.77 7,749 -30.53 0.0130
2016-08-15 2016-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 547,589 395,548 260.16 11,154 380.98 0.0255
2016-05-16 2016-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 152,041 -59,618 -28.17 2,319 -18.49 0.0058
2016-02-16 2015-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 211,659 211,659 0.00 2,845 0.0060
2015-11-16 2015-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 0 -90,291 -100.00 0 -100.00
2015-08-14 2015-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 90,291 -333,647 -78.70 1,533 -70.09 0.0029
2015-05-15 2015-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 423,938 -136,120 -24.30 5,125 10.26 0.0095
2015-02-17 2014-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 560,058 287,513 105.49 4,648 96.28 0.0098
2014-11-14 2014-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 272,545 272,545 0.00 2,368 0.0060
2014-08-14 2014-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 0 -37,659 -100.00 0 -100.00
2014-05-15 2014-03-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 37,659 -53,049 -58.48 337 -50.73 0.0010
2014-02-14 2013-12-31 13F SUPERNUS PHARMACEUTICALS COM 868459108 90,708 -90,513 -49.95 684 -48.49 0.0022
2013-11-14 2013-09-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 181,221 88,353 95.14 1,328 122.45 0.0043
2013-08-14 2013-06-30 13F SUPERNUS PHARMACEUTICALS COM 868459108 92,868 92,868 597 0.0018
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F SUPERNUS PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2026-02-17 2025-12-31 13F SUPERNUS PHARMACEUTICALS COM Call 45,000 -78.25 2,236 -77.38 n/a n/a n/a
2025-11-14 2025-09-30 13F SUPERNUS PHARMACEUTICALS COM Call 206,900 9,888 n/a n/a n/a
2023-11-14 2023-09-30 13F SUPERNUS PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2023-08-14 2023-06-30 13F SUPERNUS PHARMACEUTICALS COM Call 60,000 20.00 1,804 -0.44 n/a n/a n/a
2023-05-15 2023-03-31 13F SUPERNUS PHARMACEUTICALS COM Call 50,000 1,811 n/a n/a n/a
2022-02-14 2021-12-31 13F SUPERNUS PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2021-11-15 2021-09-30 13F SUPERNUS PHARMACEUTICALS COM Call 10,000 267 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.